SCHEMBL4598398

SCHEMBL4598398

O=C(CC(Nc1c(Nc2ccc3[nH]cnc3c2)c(=O)c1=O)c1cccc(O)c1)N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 3/20 0.41
MAPKAPK2 P49137 2/20 0.36
CYP2C9 P11712 1/20 0.36
PDGFRA P16234 1/20 0.36
PRKCA P17252 1/20 0.36
MAPK1 P28482 1/20 0.36
ROCK1 Q13464 1/20 0.36
RPS6KA1 Q15418 1/20 0.36
AURKB Q96GD4 1/20 0.36
CSNK1G1 Q9HCP0 1/20 0.36
USP7 Q93009 2/20 0.36
ROCK2 O75116 2/20 0.35
EGFR P00533 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CTSL P07711 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898077 0.91 MAPKAPK2 (0.37) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL4908818 0.85 MAPKAPK2 (0.42) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL4910847 0.82 MAPKAPK2 (0.42) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL4599129 0.81 MAPKAPK2 (0.45) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL4906181 0.80 MAPKAPK2 (0.40) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL14066741 0.78 HPGD (0.38) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL14066740 0.78 MAPKAPK2 (0.38) CXCR2MAPKAPK2CYP2C9PDGFRAPRKCA
SCHEMBL4596962 0.76 MAPKAPK2 (0.61) MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1
SCHEMBL4598811 0.76 MAPKAPK2 (0.61) MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1
SCHEMBL4598110 0.76 MAPKAPK2 (0.49) MAPKAPK2CYP2C9PDGFRAPRKCAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US claimed
EP-1910312-A1 QUADRATIC ACID II DERIVATIVES Merck Patent GmbH (DE) 2008-04-16 EP claimed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO claimed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234266-A1 Squaric Acid Derivatives II CHEK2, CHEK1, SGK3 CXCR2 1478/4885MAPKAPK2 346/4885CYP2C9 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.